Future applications of 3D bioprinting: A promising technology for treating recessive dystrophic epidermolysis bullosa

Three‐dimensional (3D) bioprinting is a rapidly developing technology that has the potential to initiate a paradigm shift in the treatment of skin wounds arising from burns, ulcers and genodermatoses. Recessive dystrophic epidermolysis bullosa (RDEB), a severe form of epidermolysis bullosa, is a rar...

Full description

Saved in:
Bibliographic Details
Published in:Experimental dermatology 2022-03, Vol.31 (3), p.384-392
Main Authors: Popp, Courtney M., Miller, William C., Eide, Cindy R., Tolar, Jakub
Format: Article
Language:English
Subjects:
3-D printers
Bioprinting
Burns
Dystrophic epidermolysis bullosa
Epidermolysis bullosa
Epidermolysis Bullosa Dystrophica - therapy
gene editing
Genodermatosis
guided tissue regeneration
Humans
regenerative medicine
Skin
Technology
tissue engineering
Trauma
Ulcers
Wound Healing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Three‐dimensional (3D) bioprinting is a rapidly developing technology that has the potential to initiate a paradigm shift in the treatment of skin wounds arising from burns, ulcers and genodermatoses. Recessive dystrophic epidermolysis bullosa (RDEB), a severe form of epidermolysis bullosa, is a rare genodermatosis that results in mechanically induced blistering of epithelial tissues that leads to chronic wounds. Currently, there is no cure for RDEB, and effective treatment is limited to protection from trauma and extensive bandaging. The care of chronic wounds and burns significantly burdens the healthcare system, further illustrating the dire need for more beneficial wound care. However, in its infancy, 3D bioprinting offers therapeutic potential for wound healing and could be a breakthrough technology for the treatment of rare, incurable genodermatoses like RDEB. This viewpoint essay outlines the promise of 3D bioprinting applications for treating RDEB, including skin regeneration, a delivery system for gene‐edited cells and small molecules, and disease modelling. Although the future of 3D bioprinting is encouraging, there are many technical challenges to overcome–including optimizing bioink and cell source–before this approach can be widely implemented in clinical practice.
ISSN:0906-6705
1600-0625
DOI:10.1111/exd.14484